ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Exclusive license agreement with ALK-Abelló to commercialize neffy ® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royalties Well-capitalized with $349.
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Building on its collaboration with Enable Injections, Serina presented a case study at the 14th Annual Injectables Summit in Boston, MA, detailing the combination of Serina’s lead candidate, SER-252 (POZ-apomorphine),
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class (i) targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30,
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Detailed price information for Seres Therapeutics Inc (MCRB-Q) from The Globe and Mail including charting and trades.
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective ...
Yahoo Finance2d
Vivos Therapeutics, Inc. (VVOS)
Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of ...
Hosted on MSN7mon
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
VVOS Stock Movement on Tuesday VVOS stock is seeing heavy trading today alongside its CARE Medicare approval. That has more than 2.7 million shares changing hands as of this writing. This is well ...
Benzinga.com1mon
Vivos Therapeutics (NASDAQ:VVOS) Stock Quotes, Forecast and News Summary
Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering.
Mena FN1mon
Investornewsbreaks Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage For Vivos CARE Oral Medical Devices
(MENAFN- Investor Brand Network) Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company specializing in the development and commercialization of highly effective proprietary treatments ...
Hosted on MSN1mon
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep ...
Benzinga.com8mon
Vivos Therapeutics (NASDAQ:VVOS) Stock, Short Interest Report
Short interest in Vivos Therapeutics Inc (NASDAQ:VVOS) increased during the last reporting period, rising from 56.86K to 63.71K. This put 2.57% of the company's publicly available shares short.
Seeking Alpha4y
VVOS Vivos Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Nasdaq3y
Vivos Therapeutics, Inc. Common Stock (VVOS)
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...